Link to this page
Biological and Environmental Research Ontology
| Preferred Name | Tocilizumab | |
| Synonyms |
|
|
| Definitions |
A recombinant, humanized IgG1 monoclonal antibody directed against the interleukin-6 receptor (IL-6R) with immunosuppressant activity. Tocilizumab targets and binds to both the soluble form of IL-6R (sIL-6R) and the membrane-bound form (mIL-6R), thereby blocking the binding of IL-6 to its receptor. This prevents IL-6-mediated signaling. IL-6, a pro-inflammatory cytokine that plays an important role in the regulation of the immune response, is overproduced in autoimmune disorders, certain types of cancers and possibly various other inflammatory conditions. |
|
| ID |
http://purl.obolibrary.org/obo/NCIT_C84217 |
|
| Accepted_Therapeutic_Use_For |
Treatment of COVID-19-emergency use authorization (EUA).
|
|
| CAS_Registry |
375823-41-9
|
|
| CHEBI_ID |
CHEBI:64360
|
|
| code |
C84217
|
|
| Contributing_Source |
CTRP FDA
|
|
| definition |
A recombinant, humanized IgG1 monoclonal antibody directed against the interleukin-6 receptor (IL-6R) with immunosuppressant activity. Tocilizumab targets and binds to both the soluble form of IL-6R (sIL-6R) and the membrane-bound form (mIL-6R), thereby blocking the binding of IL-6 to its receptor. This prevents IL-6-mediated signaling. IL-6, a pro-inflammatory cytokine that plays an important role in the regulation of the immune response, is overproduced in autoimmune disorders, certain types of cancers and possibly various other inflammatory conditions.
|
|
| Display_Name |
Tocilizumab
|
|
| FDA_UNII_Code |
I031V2H011
|
|
| Has_Target | ||
| in_subset |
http://purl.obolibrary.org/obo/NCIT_C63923 http://purl.obolibrary.org/obo/NCIT_C173383 http://purl.obolibrary.org/obo/NCIT_C173381 http://purl.obolibrary.org/obo/NCIT_C177537 http://purl.obolibrary.org/obo/NCIT_C176424 http://purl.obolibrary.org/obo/NCIT_C116977 http://purl.obolibrary.org/obo/NCIT_C116978 http://purl.obolibrary.org/obo/NCIT_C128784 |
|
| Is_Value_For_GDC_Property | ||
| label |
Tocilizumab
|
|
| Maps_To |
Tocilizumab
|
|
| NCI_Drug_Dictionary_ID |
713832
|
|
| PDQ_Closed_Trial_Search_ID |
713832
|
|
| PDQ_Open_Trial_Search_ID |
713832
|
|
| Preferred_Name |
Tocilizumab
|
|
| prefixIRI |
NCIT:C84217
|
|
| prefLabel |
Tocilizumab
|
|
| Semantic_Type |
Pharmacologic Substance
|
|
| UMLS_CUI |
C1609165
|
|
| subClassOf |
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |